Top-funded digital health companies offering lifestyle interventions for dementia prevention: Company overview and evidence analysis

Background and objective Dementia prevention has been recognized as a top priority by public health authorities due to the lack of a reversible cure. In this regard, digital dementia-preventive lifestyle services (DDLS) emerge as potentially pivotal services, aiming to address modifiable risk factors on a large scale. This study aims to identify the top-funded companies offering DDLS and evaluate their clinical evidence to gain insights into the international service landscape. Methods A systematic screening of two financial databases (Pitchbook and Crunchbase) was conducted. Corresponding published clinical evidence was collected through a systematic literature review and analyzed regarding study purpose, results, quality of results, and level of clinical evidence. Findings The ten top-funded companies offering DDLS received a total funding of EUR 128.52 million, of which three companies collected more than 75%. Clinical evidence was limited due to only nine eligible publications, small clinical subject groups, the absence of longitudinal study designs, and no direct evidence of dementia prevention. Conclusion Our study shows that the level of funding received by companies does not reflect the clinical effectiveness of DDLS. The study serves as an initial step toward understanding how DDLS are currently evaluated in today’s market and highlights the need for a more rigorous evaluation of DDLS effectiveness.